Valneva SE
S4V2
Shigellosis
Resolved
7days ago
Phase 2 readout · Jun 30, 2026
What's at stake
Phase 2 trial results for S4V2 in Shigellosis are due Jun 30, 2026. A clean hit validates the program; a miss can gap the stock down hard.
Primary source
· SEC 6-K
verified 14h ago
“First Phase 2 data for tetravalent Shigella vaccine candidate S4V2 are expected mid-2026,”